Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia

Talha Badar, Damian R. Handisides, Juliana M. Benito, Mary Ann Richie, Gautam Borthakur, Elias Jabbour, Karine Harutyunyan, Sergej Konoplev, Stefan Faderl, Stew Kroll, Michael Andreeff, Tillman Pearce, Hagop M. Kantarjian, Jorge E. Cortes, Deborah A. Thomas, Marina Konopleva

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Tumor hypoxia causes resistance to radiation and chemotherapy. Evofosfamide (TH-302) has exhibited specific hypoxia-dependent cytotoxicity against primary acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) samples in vitro. Based on these findings, a Phase I study of evofosfamide was designed for patients with relapsed/refractory leukemia (NCT01149915). In this open-label study, patients were treated with evofosfamide as a 30–60 min/day infusion on Days 1–5 of a 21–day cycle (Arm A, n = 38) or as a continuous infusion over 120 hr over Days 1–5 of a 21-day cycle (Arm B, n = 11). Forty-nine patients were treated including 39 (80%) with AML and 9 (18%) with ALL. Patients had received a median of five prior therapies. In Arm A, the dose-limiting toxicities (DLTs) were grade 3 esophagitis, observed at a dose of 550 mg/m2. The maximum tolerated dose (MTD) was a daily dose of 460 mg/m2. In Arm B, the DLTs were grade 3 stomatitis and hyperbilirubinemia, observed at a daily dose of 460 mg/m2. The continuous infusion MTD was a daily dose of 330 mg/m2. Hypoxia markers HIF-1α and CAIX were highly expressed in leukemic bone marrow and were significantly reduced after evofosfamide therapy. The combined overall response rate in Arms A and B was 6% (2 CR/CRi and 1 PR), with all responses seen in Arm A. Evofosfamide has shown limited activity in heavily pretreated leukemia patients. Further evaluation investigating evofosfamide in combination with cytotoxic or demethylating agents is warranted. Am. J. Hematol. 91:800–805, 2016.

Original languageEnglish (US)
Pages (from-to)800-805
Number of pages6
JournalAmerican Journal of Hematology
Volume91
Issue number8
DOIs
StatePublished - Aug 1 2016

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia'. Together they form a unique fingerprint.

  • Cite this

    Badar, T., Handisides, D. R., Benito, J. M., Richie, M. A., Borthakur, G., Jabbour, E., Harutyunyan, K., Konoplev, S., Faderl, S., Kroll, S., Andreeff, M., Pearce, T., Kantarjian, H. M., Cortes, J. E., Thomas, D. A., & Konopleva, M. (2016). Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. American Journal of Hematology, 91(8), 800-805. https://doi.org/10.1002/ajh.24415